Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model.
Mosier
D E
DE
Medical Biology Institute, La Jolla, CA 92037.
Gulizia
R J
RJ
MacIsaac
P
P
Mathieson
B J
BJ
Smith
G
G
Hu
S L
SL
Corey
L
L
Greenberg
P
P
D016915:AIDS Vaccines; D000818:Animals; D015686:Gene Products, env / Q000008:administration & dosage / Q000276:immunology*; D006085:Graft Survival; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D016219:Immunotherapy, Adoptive; D051379:Mice; D016513:Mice, SCID / Q000276:immunology*; D011498:Protein Precursors / Q000008:administration & dosage / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D014183:Transplantation, Heterologous; D014616:Vaccinia virus
D016915:AIDS Vaccines; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011994:Recombinant Proteins